- SynonymBMPR-1A,ALK-3,10q23del,ACVRLK3,CD292,SKR5
- SourceHuman BMPR-IA, His Tag (AL3-H5228) is expressed from human 293 cells (HEK293). It contains AA Gln 24 - Arg 152 (Accession # P36894-1).Predicted N-terminus: Gln 24Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 15.0 kDa. The protein migrates as 23-34 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human BMPR-IA, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
- BackgroundThe bone morphogenetic protein receptor, type IA is also known as BMPR1A or ALK3 is a protein which in humans is encoded by the BMPR1A gene. BMPR1A has also been designated as CD292 (cluster of differentiation 290). The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A (this protein) and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. Alk3-mediatedBMP signaling in AV endocardial/mesenchymal cells plays a central role during cushion morphogenesis.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
反应体系如下:
plasmid10ul
10xKbuffer5ul
KpnI1ul
BamHI1ul注意千万不可多加总酶量必须<4%
ddH20upto50ul
总体积改变加酶量按比例改变.
因为溶蛋白酶是蛋白质本质的酶
如果能分解,那小肠液中的消化酶如何大量共存,如果不能
那它如何识别其他蛋白质物质是不是消化酶?
炎性体（inflammasome）是细胞内的一类多蛋白复合物，在炎性反应中发挥着至关重要的作用。炎性体包括半胱天冬酶-1（caspase1）、PYCARD和NALP，有时也包括半胱天冬酶-5（caspase5，也被称作半胱天冬酶-11或ICH-3）。它是在骨髓细胞（myeloidcell）中产生的，也是先天性免疫系统的一个组分。炎性体的确切组成依赖于启动炎性体组装的激活物，如双链RNA和石棉会引发不同的炎性体组成。炎性体促进炎性细胞因子IL-1β和IL-18成熟。
在一项新的研究中，来自比利时法兰德斯生物技术中心/根特大学（VIB/UGent）的LieselotteVandeWalle博士、DanielJiménezFernández以及教授MoLamkanfi研究团队对半胱天冬酶-12（caspase12）的功能产生新的认识。基于此，他们打破了这个领域对半胱天冬酶-12的固执观念：半胱天冬酶-12是炎性体的负调节物。这些新的认识为研究人员挣脱现有的研究路线和鉴定它的真正生理学功能铺平道路。相关研究结果发表在2016年6月2日那期Nature期刊上，论文标题为“Doescaspase-12suppressinflammasomeactivation?”。
研究人员也指出这将需要进行大量的“重新研究（re-researching）”。之前所谓的半胱天冬酶-12在细胞死亡、应激反应、疟疾和败血症等中的作用---引用了9000多次---必需复核，这是因为这些作用经常是基于不正确的小鼠模型得出的。
VIB/UGent教授MoLamkanfi说，“我们发现在很多情形下，对半胱天冬酶-12的研究是基于对半胱天冬酶-11（caspase11）和半胱天冬酶-12都进行基因敲除的小鼠模型开展的。因此从研究结果中推断半胱天冬酶-12的作用是不可能的。我们如今引入新的选择性半胱天冬酶-12基因敲除小鼠，这应当能够让我们追踪半胱天冬酶-12的确切功能。”
利用这些新的小鼠，Lamkanfi团队证实在体外模拟的BMDM（bonemarrow-derivedmacrophage,骨髓衍生性巨噬细胞）和体内接种的小鼠中，半胱天冬酶-12缺乏都不能增加半胱天冬酶-1激活。剔除半胱天冬酶-12也不会增强炎性体途径释放出成熟的IL-1β和IL-18。他们的发现表明不论半胱天冬酶-11的表达状态如何，半胱天冬酶-12都不会作为半胱天冬酶-1激活的生理学上负显性调节物，因而也不会作为炎性体的生理学上负显性调节物。
